<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ranolazine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ranolazine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ranolazine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11572" href="/d/html/11572.html" rel="external">see "Ranolazine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F2528121"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Aspruzyo Sprinkle;</li>
<li>Ranexa [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F55868469"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Corzyna</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F2528123"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antianginal Agent;</li>
<li>
                        Cardiovascular Agent, Miscellaneous</li></ul></div>
<div class="block doa drugH1Div" id="F2528161"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c77b05f5-c1b5-4af8-ba05-d3f8c5a7158a">Chronic angina</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic angina:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May be used in combination with beta-blockers, nitrates, or calcium channel blockers, or may serve as a substitute for these routine antianginal therapies if they are not tolerated due to side effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23166211']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23166211'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 500 mg twice daily; may increase to 1,000 mg twice daily as needed (based on symptoms); maximum recommended dose: 1,000 mg twice daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="eeb56557-d04f-4aef-94c0-13a4a91593d9">Ventricular tachycardia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ventricular tachycardia (off-label use): Oral:</b> 500 to 1,000 mg every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29084731','lexi-content-ref-21895727','lexi-content-ref-17804441']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29084731','lexi-content-ref-21895727','lexi-content-ref-17804441'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991191"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &gt;80 mL/minute: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16153399']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16153399'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &gt;30 to 80 mL/minute: No dosage adjustment necessary; however, there is significant interpatient variability in pharmacokinetics and almost doubling of AUC compared to patients with normal renal function. Use with caution, especially in patients with CrCl &lt;50 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16153399','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16153399','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≤30 mL/minute:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Use with extreme caution; acute kidney injury and other adverse effects (eg, neurologic) have been observed in some patients with severe kidney impairment.</p>
<p style="text-indent:-2em;margin-left:6em;">Initial: 500 mg once daily; maximum: 500 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16153399','lexi-content-ref-Kalra.1','lexi-content-ref-17456819','lexi-content-ref-23307553']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16153399','lexi-content-ref-Kalra.1','lexi-content-ref-17456819','lexi-content-ref-23307553'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not likely to be significantly dialyzed (moderate plasma protein binding and large V<sub>d</sub>): Avoid use (preferred) or dose as for CrCl ≤30 mL/minute with extreme caution and close monitoring for adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>); variable absorption was observed in a small pharmacokinetic study of patients on hemodialysis, limiting the ability to recommend a safe and effective dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30909832']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30909832'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Has not been studied; avoid use (preferred) or dose as for CrCl ≤30 mL/minute with extreme caution and close monitoring for adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988246"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. Use is contraindicated with hepatic cirrhosis.</p></div>
<div class="block doe drugH1Div" id="F2528162"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing. Select dose cautiously, starting at the lower end of the dosing range.</p></div>
<div class="block arsc drugH1Div" id="F58721334"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">QT prolongation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Use of ranolazine has been associated with <b>prolonged QT interval on ECG</b>. The increase in the mean duration of the QTc interval at therapeutic doses is generally modest (~5 to 10 msec) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15378132','lexi-content-ref-14734593','lexi-content-ref-15093870','lexi-content-ref-17349881','lexi-content-ref-15378133']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15378132','lexi-content-ref-14734593','lexi-content-ref-15093870','lexi-content-ref-17349881','lexi-content-ref-15378133'])">Ref</a></span>); a greater increase (~15 msec) may be seen at higher doses and/or concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15093870','lexi-content-ref-Ranexa.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15093870','lexi-content-ref-Ranexa.1'])">Ref</a></span>). Rare cases of ranolazine-associated <b>torsades de pointes</b> (TdP) have been reported in the presence of other risk factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24396259','lexi-content-ref-17456819']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24396259','lexi-content-ref-17456819'])">Ref</a></span>). When compared to pure KCNH2 channel inhibitors (formerly called hERG channel) (eg, dofetilide), drugs with combined KCNH2 channel and inward current blockers (calcium or late sodium) (eg, ranolazine) may have a lower risk of TdP (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25054430']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25054430'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-dependent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14734593','lexi-content-ref-15093870']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14734593','lexi-content-ref-15093870'])">Ref</a></span>); related to the pharmacologic action. Ranolazine exhibits multichannel effect including blockade of inward depolarizing currents (ie, late sodium, late L-type calcium, inward sodium-calcium exchanger, and peak L-type calcium currents) and outward repolarizing currents (ie, slow and rapid component of the delayed rectifier potassium currents); as a result, there is a minimal prolongation in the action potential duration and the resulting potential for QT interval prolongation is modest (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34386127','lexi-content-ref-15378132']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34386127','lexi-content-ref-15378132'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied. The effect of ranolazine on the QT segment is concentration-dependent; therefore, the timing of QT prolongation may be impacted by the presence of risk factors that result in increased concentrations (eg, hepatic impairment, drug interactions) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15378132','lexi-content-ref-24396259','lexi-content-ref-17456819']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15378132','lexi-content-ref-24396259','lexi-content-ref-17456819'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Ranolazine-induced QTc prolongation:</p>
<p style="text-indent:-2em;margin-left:8em;">• Higher doses (eg, &gt;2,000 mg/day)</p>
<p style="text-indent:-2em;margin-left:8em;">• Moderate hepatic impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15951470']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15951470'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Genetic predisposition to or preexisting long QT syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24574825','lexi-content-ref-17296457','lexi-content-ref-28213480']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24574825','lexi-content-ref-17296457','lexi-content-ref-28213480'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concomitant administration of drugs known to prolong the QT interval (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24574825','lexi-content-ref-17296457','lexi-content-ref-25438492','lexi-content-ref-24424337']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24574825','lexi-content-ref-17296457','lexi-content-ref-25438492','lexi-content-ref-24424337'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concomitant administration of drugs that inhibit CYP3A4 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24574825','lexi-content-ref-17296457','lexi-content-ref-25438492']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24574825','lexi-content-ref-17296457','lexi-content-ref-25438492'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Drug-induced QTc prolongation/torsades de pointes (TdP) (in general):</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Age &gt;65 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Structural heart disease (eg, history of myocardial infarction or heart failure with reduced ejection fraction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Genetic defects of cardiac ion channels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• History of drug-induced TdP (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Congenital long QT syndrome (LQTS) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Baseline QTc interval prolongation (eg, &gt;500 msec) or lengthening of the QTc by ≥60 milliseconds (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Electrolyte disturbances (eg, hypocalcemia, hypokalemia, or hypomagnesemia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Bradycardia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Hepatic impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Loop diuretic use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24803473']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24803473'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Sepsis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24803473']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24803473'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concurrent administration of multiple medications (≥2) that prolong the QT interval or medications with drug interactions that increase serum concentrations of QT-prolonging medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F2528126"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia (≤4%), hypotension (≤4%), orthostatic hypotension (≤4%), palpitations (≤4%), peripheral edema (≤4%), syncope (≤4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Hyperhidrosis (≤4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (≤4%), anorexia (≤4%), constipation (5%), dyspepsia (≤4%), nausea (4%), vomiting (≤4%), xerostomia (≤4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hematuria (≤4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (≤4%), confusion (≤4%), dizziness (6%; may be dose-related), headache (6%), vertigo (≤4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (≤4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus (≤4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (≤4%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urine discoloration</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Eosinophilia, leukopenia, pancytopenia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Hypoesthesia, paresthesia, tremor</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen, kidney failure</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pulmonary fibrosis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flattened T wave on ECG (Vicente 2015), inversion T wave on ECG (Kumthekar 2015), notching of T wave on ECG (Vicente 2015), prolonged QT interval on ECG (Vadnais 2010), torsades de pointes (Liu 2013; Morrow 2007)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis (Grelck 2015), pruritus, skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysuria, urinary retention</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Ataxia, hallucination, myoclonus (Porhomayon 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Increased creatine phosphokinase in blood specimen (Dein 2018), myalgia (Dein 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine</p></div>
<div class="block coi drugH1Div" id="F2528125"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic cirrhosis; concurrent use of strong CYP3A inhibitors; concurrent use of CYP3A inducers.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to ranolazine or any component of the formulation; concurrent use of class Ia antiarrhythmics (eg, quinidine, procainamide, disopyramide) or class III antiarrhythmics (eg, sotalol, ibutilide, amiodarone, dronedarone); severe renal impairment (GFR ≤30 mL/minute/1.73 m<sup>2</sup>); moderate or severe hepatic impairment.</p></div>
<div class="block war drugH1Div" id="F2528143"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acute coronary syndrome: Ranolazine will not relieve acute angina episode and has not demonstrated benefit in acute coronary syndrome.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Ranolazine plasma levels increase by 30% in patients with mild (Child-Pugh class A) and by 80% in patients with moderate (Child-Pugh class B) hepatic impairment. Use is contraindicated in patients with cirrhosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Acute renal failure has been observed in some patients with severe renal impairment (CrCl &lt;30 mL/minute); if acute renal failure develops (marked increase in serum creatinine associated with increased BUN), discontinue ranolazine and manage appropriately. Monitor renal function periodically in patients with moderate to severe renal impairment; particularly for increases in serum creatinine accompanied by increased BUN. In a renal impairment study, patients with severe impairment exhibited an initial elevation in diastolic BP (~12 to 17 mm Hg at day 3), however, this diminished to ~4 mm Hg increase by day 5 (Jerling 2005); consider monitoring BP in patients with renal dysfunction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CYP3A inhibitors: Use is contraindicated with inducers and strong inhibitors of CYP3A.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in patients ≥75 years of age; they may experience more adverse events (including serious adverse events) and drug discontinuations due to adverse events.</p></div>
<div class="block foc drugH1Div" id="F2528167"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Packet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Aspruzyo Sprinkle: 500 mg (60 ea); 1000 mg (60 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 12 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ranexa: 500 mg [DSC], 1000 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg, 1000 mg</p></div>
<div class="block geq drugH1Div" id="F2528139"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F3422174"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pack</b> (Aspruzyo Sprinkle Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $6.07</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 mg (per each): $9.96</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 12-hour</b> (Ranolazine ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $6.42 - $7.40</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 mg (per each): $10.54 - $12.15</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F55868470"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 12 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Corzyna: 500 mg, 1000 mg</p></div>
<div class="block adm drugH1Div" id="F2528135"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Granules: Sprinkle granules on 1 tablespoonful of soft food (eg, applesauce, yogurt) and swallow immediately; do not crush or chew.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet: Administer with or without meals. Swallow tablet whole; do not crush, break, or chew.</p>
<p style="text-indent:-2em;margin-left:6em;">Bariatric surgery: Granules, extended release; Tablet, extended release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. There are no IR formulations available. If safety and efficacy can be effectively monitored, no change in formulation or administration is required after bariatric surgery; however, close clinical monitoring is advised in the immediate postoperative phase for the theoretical circumstance of reduced absorption after bariatric surgery.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastric tube: </b>Granules: Add contents of 1 sachet to a plastic catheter tip syringe and add 30 mL of water; gently shake for ~15 seconds and immediately administer through a 12 French or larger NG tube. Rinse with 20 mL of water. Rinse with an additional water (~15 mL) if needed to ensure granules are not left in the syringe.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>NG tube:</b> Granules: Add contents of 1 sachet to a plastic catheter tip syringe and add 50 mL of water; gently shake for ~15 seconds and immediately administer through a 12 French or larger NG tube. Rinse with additional water (~15 mL) if needed to ensure granules are not left in the syringe.</p></div>
<div class="block use drugH1Div" id="F2528140"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Chronic angina:</b> Treatment of chronic angina.</p></div>
<div class="block off-label drugH1Div" id="F51359559"><span class="drugH1">Use: Off-Label: Adult</span><p>Ventricular tachycardia</p></div>
<div class="block mst drugH1Div" id="F4431159"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Ranexa [DSC] may be confused with CeleXA, PreNexa Premier</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F2528147"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2D6 (minor), CYP3A4 (major), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2D6 (weak), CYP3A4 (weak), OCT2, P-glycoprotein/ABCB1</p></div>
<div class="block dri drugH1Div" id="F2528146"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Afatinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Afatinib.  Management: If combined, administer the P-gp inhibitor simultaneously with, or after, the dose of afatinib. Monitor closely for signs and symptoms of afatinib toxicity and if the combination is not tolerated, reduce the afatinib dose by 10 mg.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May increase the serum concentration of Ranolazine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aliskiren: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Aliskiren. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALPRAZolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ALPRAZolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin II Receptor Blockers: Ranolazine may enhance the adverse/toxic effect of Angiotensin II Receptor Blockers. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin-Converting Enzyme Inhibitors: Ranolazine may enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Berotralstat: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Berotralstat.  Management: Decrease the berotralstat dose to 110 mg daily when combined with P-glycoprotein (P-gp) inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bilastine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bilastine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Celiprolol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Celiprolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofarabine: OCT2 Inhibitors may increase the serum concentration of Clofarabine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: This combination is often contraindicated, but combined use may be permitted with dose adjustment and monitoring. Recommendations vary based on brand, indication, use of CYP3A4 inhibitors, and hepatic/renal function. See interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): CYP3A4 Inhibitors (Weak) may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Ranolazine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Ranolazine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Ranolazine. Management: Limit the ranolazine dose to a maximum of 500 mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors. Monitor for increased ranolazine effects and toxicities during concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Ranolazine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dalfampridine: OCT2 Inhibitors may increase the serum concentration of Dalfampridine.  Management: Consider alternatives to this combination. Carefully weigh the risk of seizures against the benefit of combining OCT2 inhibitors with dalfampridine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Digoxin: Ranolazine may increase the serum concentration of Digoxin.  Management: Measure digoxin serum concentrations before initiating treatment with ranolazine. Reduce digoxin concentrations by either reducing the digoxin dose by 30% to 50% or by modifying the dosing frequency.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dofetilide: OCT2 Inhibitors may increase the serum concentration of Dofetilide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Conventional): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of DOXOrubicin (Conventional). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of DOXOrubicin (Liposomal). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edoxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Edoxaban. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Etoposide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide Phosphate: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Etoposide Phosphate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Finerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flibanserin: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Flibanserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glecaprevir and Pibrentasvir: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Glecaprevir and Pibrentasvir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Ixabepilone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lapatinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Lapatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Larotrectinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Larotrectinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Lefamulin.  Management: Avoid concomitant use of lefamulin tablets with P-glycoprotein/ABCB1 inhibitors. If concomitant use is required, monitor for lefamulin adverse effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lemborexant.  Management: The maximum recommended dosage of lemborexant is 5 mg, no more than once per night, when coadministered with weak CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Patients on lomitapide 5 mg/day may continue that dose. Patients taking lomitapide 10 mg/day or more should decrease the lomitapide dose by half. The lomitapide dose may then be titrated up to a max adult dose of 30 mg/day.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lovastatin: Ranolazine may increase the serum concentration of Lovastatin. Ranolazine may also enhance the distribution of lovastatin to specific cells/tissues/organs where P-glycoprotein is present in large amounts (eg, brain, T-lymphocytes, testes, etc.).  Management: Consider a lovastatin dose reduction if combined with ranolazine. An American Heart Association scientific statement recommends limiting lovastatin doses to 20 mg daily when used with ranolazine. Monitor closely for lovastatin toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mavacamten: Ranolazine may enhance the adverse/toxic effect of Mavacamten. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetFORMIN: Ranolazine may increase the serum concentration of MetFORMIN.  Management: Limit the metformin dose to a maximum of 1,700 mg per day when used together with ranolazine 1,000 mg twice daily. Monitor patients for metformin toxicities, including lactic acidosis and carefully weigh the risks and benefits of this combination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midazolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Midazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Morphine (Systemic): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Morphine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadolol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Nadolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naldemedine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naloxegol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Naloxegol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of Ranolazine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pralsetinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Pralsetinib.  Management: If this combo cannot be avoided, decrease pralsetinib dose from 400 mg daily to 300 mg daily; from 300 mg daily to 200 mg daily; and from 200 mg daily to 100 mg daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Red Yeast Rice: Ranolazine may increase the serum concentration of Red Yeast Rice. Ranolazine may also enhance the distribution of lovastatin, a component of red yeast rice, to specific cells/tissues/organs where P-glycoprotein is present in large amounts (eg, brain, T-lymphocytes, testes, etc.).  Management: Consider reducing the dose of red yeast rice if combined with ranolazine. An American Heart Association scientific statement recommends limiting lovastatin doses to 20 mg daily when used with ranolazine. Red yeast rice interacts similarly.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Relugolix: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Relugolix.  Management: Avoid coadministration of relugolix with oral P-gp inhibitors whenever possible. If combined, take relugolix at least 6 hours prior to the P-gp inhibitor and monitor patients more frequently for adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Relugolix, Estradiol, and Norethindrone: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Relugolix, Estradiol, and Norethindrone.  Management: Avoid use of relugolix/estradiol/norethindrone with P-glycoprotein (P-gp) inhibitors. If concomitant use is unavoidable, relugolix/estradiol/norethindrone should be administered at least 6 hours before the P-gp inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repotrectinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Repotrectinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAXIMin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of RifAXIMin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rimegepant: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rimegepant.  Management: Avoid administration of another dose of rimegepant within 48 hours if given concomitantly with a P-glycoprotein (P-gp) inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of RisperiDONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RomiDEPsin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of RomiDEPsin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simvastatin: Ranolazine may increase the serum concentration of Simvastatin.  Management: Carefully consider the potential benefits and risks of this combination. Limit simvastatin to 20 mg daily if coadministered, and monitor closely for signs and symptoms of myopathy or rhabdomyolysis.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Sirolimus (Conventional).  Management: Avoid concurrent use of sirolimus with P-glycoprotein (P-gp) inhibitors when possible and alternative agents with lesser interaction potential with sirolimus should be considered. Monitor for increased sirolimus concentrations/toxicity if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Sirolimus (Protein Bound). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talazoparib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Talazoparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tegaserod (Withdrawn from US Market): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Tegaserod (Withdrawn from US Market). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teniposide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Teniposide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tenofovir Disoproxil Fumarate: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Tenofovir Disoproxil Fumarate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thioridazine: CYP2D6 Inhibitors (Weak) may increase the serum concentration of Thioridazine.  Management: Consider avoiding concomitant use of thioridazine and weak CYP2D6 inhibitors. If combined, monitor closely for QTc interval prolongation and arrhythmias. Some weak CYP2D6 inhibitors list use with thioridazine as a contraindication.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triazolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Triazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Ubrogepant.  Management: In patients taking weak CYP3A4 inhibitors, the initial and second dose (given at least 2 hours later if needed) of ubrogepant should be limited to 50 mg.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Venetoclax: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Venetoclax.  Management: Reduce the venetoclax dose by at least 50% in patients requiring concomitant treatment with P-glycoprotein (P-gp) inhibitors. Resume the previous venetoclax dose 2 to 3 days after discontinuation of a P-gp inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal). <i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F6814825"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Grapefruit, grapefruit juice, or grapefruit-containing products may increase the serum concentration of ranolazine. Management: Limit ranolazine dose to a maximum of 500 mg twice daily in patients concurrently consuming grapefruit juice; monitor for increased effects/toxicity.</p></div>
<div class="block pri drugH1Div" id="F2528141"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events have been observed in animal reproduction studies. </p></div>
<div class="block brc drugH1Div" id="F6814824"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if ranolazine is excreted into breast milk. According to the manufacturer, the decision to breastfeed during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.</p></div>
<div class="block dic drugH1Div" id="F2528157"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Limit the use of grapefruit juice; the ranolazine dose should not exceed 500 mg twice daily when taken with grapefruit juice or grapefruit-containing products.</p></div>
<div class="block mop drugH1Div" id="F2528165"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Baseline and follow up ECG to evaluate QT interval; monitor renal function periodically in patients with moderate to severe renal impairment, particularly for increases in serum creatinine accompanied by increased BUN; consider monitoring blood pressure in patients with renal dysfunction; correct and maintain serum potassium in normal limits</p></div>
<div class="block pha drugH1Div" id="F2528158"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Ranolazine exerts antianginal and anti-ischemic effects without changing hemodynamic parameters (heart rate or blood pressure). At therapeutic levels, ranolazine inhibits the late phase of the inward sodium channel (late I<sub>Na</sub>) in ischemic cardiac myocytes during cardiac repolarization reducing intracellular sodium concentrations and thereby reducing calcium influx via Na<sup>+</sup>-Ca<sup>2+</sup> exchange. Decreased intracellular calcium reduces ventricular tension and myocardial oxygen consumption. It is thought that ranolazine produces myocardial relaxation and reduces anginal symptoms through this mechanism although this is uncertain. At higher concentrations, ranolazine inhibits the rapid delayed rectifier potassium current (I<sub>Kr</sub>) thus prolonging the ventricular action potential duration and subsequent prolongation of the QT interval.  </p></div>
<div class="block phk drugH1Div" id="F2528133"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Highly variable.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~62%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensive; Hepatic via CYP3A (major) and 2D6 (minor); intestines.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 76% (compared to solution).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Ranolazine: Terminal: 7 hours; Metabolites (active and inactive [Yao 2009]): 6 to 22 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: 2 to 5 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Primarily urine (75% mostly as active and inactive metabolites; &lt;5% as unchanged drug); feces (25% mostly as active and inactive metabolites; &lt;5% as unchanged drug).</p></div>
<div class="block phksp drugH1Div" id="F51220831"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: AUC<sub>0-12 </sub>geometric mean ratio values 1.72, 1.8, and 1.97 in patients with CrCl &gt;50 to 80 mL/minute, 30 to 50 mL/minute, and &lt;30 mL/minute, respectively, versus patients with normal kidney function. CVT-2738 (active metabolite) AUC<sub>0-12 </sub>increased 81%, 276%, and 375% in patients with CrCl &gt;50 to 80 mL/minute, 30 to 50 mL/minute, and &lt;30 mL/minute, respectively, versus patients with normal kidney function (Jerling 2005).</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: C<sub>max</sub> is increased by 30% in cirrhotic patients with mild (Child-Pugh class A) hepatic impairment and 80% in cirrhotic patients with moderate (Child-Pugh class B) hepatic impairment.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F11390213"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Ranexa</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Ranexa</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Ralozine | Ranola | Ranolin | Ranozex</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Ranexa</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Riscard</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Ranexa</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Civenistu | Ranexicor</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Ranexa</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Ranexa | Ranolazina</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Ranexa</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Ranexa</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Rancv</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Ranexa</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Ranexa</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Ranexa</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Ranexa</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Ranexa</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Angicorn | Angidil sr | Angiotec | Caroza | Cartinex | Corvela | Nefazor.xr | Ran CV | Rancad | Randear | Rangil | Ranogard | Ranolaz | Ranopill | Ranozex | Ranx | Ranz | Razine | Razona | Razonin | Revulant | Rolazin | Rozo | Synx</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Ranexa</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Ranexa</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Cartinex | Rancv | Ranexa</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Ranexa sr</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Ranexa</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Ranexa</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Ranexa</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Ranexa</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Rancv</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Ranexa</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Rancv</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Ranexa | Razine</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Angibar xr | Angiwell xr | Cardazin xr | Ranagin xr | Rancard xr | Ranogen er | Ranogin er | Ranola | Ranx | Ranzol xr | Rolazin er | Valazor</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Ranexa</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Aspruzyo sprinkle | Ranolazine extended release</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Ranexa</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Ranexa</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Ranexa</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Ranexa</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Ranexa</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Ranexa</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Ranexa</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Latixa | Razina</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Rancad</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Ranexa</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Rancv</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-15951470">
<a name="15951470"></a>Abdallah H, Jerling M. Effect of hepatic impairment on the multiple-dose pharmacokinetics of ranolazine sustained release tablets. <i>J Clin Pharmacol</i>. 2005;45(7):802-809. doi:10.1177/0091270005276739<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranolazine-drug-information/abstract-text/15951470/pubmed" id="15951470" target="_blank">15951470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34386127">
<a name="34386127"></a>Akcay M, Coksevim M, Yenercag M. Effect of ranolazine on Tp-e interval, Tp-e/QTc, and P-wave dispersion in patients with stable coronary artery disease. <i>J Arrhythm</i>. 2021;37(4):1015-1022. doi:10.1002/joa3.12549<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranolazine-drug-information/abstract-text/34386127/pubmed" id="34386127" target="_blank">34386127</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24574825">
<a name="24574825"></a>Aldakkak M, Stowe DF, Camara AK. Safety and efficacy of ranolazine for the treatment of chronic angina pectoris. <i>Clin Med Insights Ther</i>. 2013;2013(5):1-14. doi:10.4137/CMT.S7824 PMC3932785.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranolazine-drug-information/abstract-text/24574825/pubmed" id="24574825" target="_blank">24574825</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29084731">
<a name="29084731"></a>Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>Circulation</i>. 2018;138(13):e272-e391. doi:10.1161/CIR.0000000000000549<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranolazine-drug-information/abstract-text/29084731/pubmed" id="29084731" target="_blank">29084731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15378132">
<a name="15378132"></a>Antzelevitch C, Belardinelli L, Wu L, et al. Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent. <i>J Cardiovasc Pharmacol Ther</i>. 2004;9 Suppl 1:S65-83. doi:10.1177/107424840400900106<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranolazine-drug-information/abstract-text/15378132/pubmed" id="15378132" target="_blank">15378132</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Aspruzyo (ranolazine) [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries Inc; February 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21895727">
<a name="21895727"></a>Bunch TJ, Mahapatra S, Murdock D, et al. Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks. <i>Pacing Clin Electrophysiol.</i> 2011;34(12):1600-1606. doi:10.1111/j.1540-8159.2011.03208.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranolazine-drug-information/abstract-text/21895727/pubmed" id="21895727" target="_blank">21895727</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14734593">
<a name="14734593"></a>Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina. A randomized controlled trial. <i>JAMA</i>. 2004a;291(3):309-316. doi:10.1001/jama.291.3.309<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranolazine-drug-information/abstract-text/14734593/pubmed" id="14734593" target="_blank">14734593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15093870">
<a name="15093870"></a>Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. <i>J Am Coll Cardiol</i>. 2004b;43(8):1375-1382. doi:10.1016/j.jacc.2003.11.045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranolazine-drug-information/abstract-text/15093870/pubmed" id="15093870" target="_blank">15093870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17296457">
<a name="17296457"></a>Cheng JW. Ranolazine for the management of coronary artery disease. <i>Clin Ther</i>. 2006;28(12):1996-2007. doi:10.1016/j.clinthera.2006.12.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranolazine-drug-information/abstract-text/17296457/pubmed" id="17296457" target="_blank">17296457</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Corzyna (ranolazine) [product monograph]. Mississauga, Ontario, Canada: KYE Pharmaceuticals Inc; December 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30131925">
<a name="30131925"></a>Dein E, Manno R, Syed A, Douglas H, Geetha D, Timlin H. Ranolazine-induced elevation of creatinine kinase in the absence of statin usage. <i>Cureus</i>. 2018;10(6):e2832. doi:10.7759/cureus.2832<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranolazine-drug-information/abstract-text/30131925/pubmed" id="30131925" target="_blank">30131925</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18041887">
<a name="18041887"></a>Dobesh PP, Trujillo TC. Ranolazine: A New Option in the Management of Chronic Stable Angina. <i>Pharmacotherapy</i>. 2007;27(12):1659-1676.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranolazine-drug-information/abstract-text/18041887/pubmed" id="18041887" target="_blank">18041887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23166211">
<a name="23166211"></a>Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. <i>Circulation</i>. 2012;126(25):e354-e347. doi:10.1161/CIR.0b013e318277d6a0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranolazine-drug-information/abstract-text/23166211/pubmed" id="23166211" target="_blank">23166211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26682297">
<a name="26682297"></a>Grelck K, Stewart N, Rosen L, Sukal S. Acute generalized exanthematous pustulosis associated with ranolazine. <i>Cutis</i>. 2015;96(4):E18-E21.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranolazine-drug-information/abstract-text/26682297/pubmed" id="26682297" target="_blank">26682297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16153399">
<a name="16153399"></a>Jerling M, Abdallah H. Effect of renal impairment on multiple-dose pharmacokinetics of extended-release ranolazine. <i>Clin Pharmacol Ther</i>. 2005;78(3):288-297. doi:10.1016/j.clpt.2005.05.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranolazine-drug-information/abstract-text/16153399/pubmed" id="16153399" target="_blank">16153399</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25054430">
<a name="25054430"></a>Johannesen L, Vicente J, Mason JW, et al. Differentiating drug-induced multichannel block on the electrocardiogram: randomized study of dofetilide, quinidine, ranolazine, and verapamil. <i>Clin Pharmacol Ther</i>. 2014;96(5):549-558. doi:10.1038/clpt.2014.155<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranolazine-drug-information/abstract-text/25054430/pubmed" id="25054430" target="_blank">25054430</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kalra.1">
<a name="Kalra.1"></a>Kalra SS, Zubin A, Nielsen C. Ranolazine and hallucinations. <i>J Med Cases.</i> 2017;8(3):90-92. doi:10.14740/jmc2774w</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17349881">
<a name="17349881"></a>Koren MJ, Crager MR, Sweeney M. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE). <i>J Am Coll Cardiol</i>. 2007;49(10):1027-1034. doi:10.1016/j.jacc.2006.10.067<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranolazine-drug-information/abstract-text/17349881/pubmed" id="17349881" target="_blank">17349881</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23500237">
<a name="23500237"></a>Kosiborod M, Arnold SV, Spertus JA, et al. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). <i>J Am Coll Cardiol</i>. 2013;61(20):2038-2045.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranolazine-drug-information/abstract-text/23500237/pubmed" id="23500237" target="_blank">23500237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25660248">
<a name="25660248"></a>Kumthekar A, Cossarini F, Shih JC, Taub CC, Massera D. Ranolazine-induced repolarization changes: A case report. <i>Am J Med</i>. 2015;128(7):e3-5. doi:10.1016/j.amjmed.2015.01.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranolazine-drug-information/abstract-text/25660248/pubmed" id="25660248" target="_blank">25660248</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24396259">
<a name="24396259"></a>Liu Z, Williams RB, Rosen BD. The potential contribution of ranolazine to Torsade de Pointe. <i>J Cardiovasc Dis Res</i>. 2013;4(3):187-190. doi:10.1016/j.jcdr.2013.08.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranolazine-drug-information/abstract-text/24396259/pubmed" id="24396259" target="_blank">24396259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25438492">
<a name="25438492"></a>Mittal SR. Slow junctional rhythm, QTc prolongation and transient torsades de-pointes following combined use of ivabradine, diltiazem and ranolazine. <i>J Assoc Physicians India</i>. 2014;62(5):426-427.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranolazine-drug-information/abstract-text/25438492/pubmed" id="25438492" target="_blank">25438492</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17456819">
<a name="17456819"></a>Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al; MERLIN-TIMI 36 Trial Investigators. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. <i>JAMA</i>. 2007;297(16):1775-1783. doi:10.1001/jama.297.16.1775<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranolazine-drug-information/abstract-text/17456819/pubmed" id="17456819" target="_blank">17456819</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23936696">
<a name="23936696"></a>Porhomayon J, Zadeii G, Yarahmadi A. A rare neurological complication of ranolazine. <i>Case Rep Neurol Med</i>. 2013;2013:451206. doi:10.1155/2013/451206<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranolazine-drug-information/abstract-text/23936696/pubmed" id="23936696" target="_blank">23936696</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ranexa.1">
<a name="Ranexa.1"></a>Ranexa (ranolazine) [prescribing information]. Foster City, CA: Gilead Sciences Inc; October 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14999113">
<a name="14999113"></a>Roden DM. Drug-induced prolongation of the QT interval. <i>N Engl J Med</i>. 2004;350(10):1013-1022. doi:10.1056/NEJMra032426<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranolazine-drug-information/abstract-text/14999113/pubmed" id="14999113" target="_blank">14999113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17804441">
<a name="17804441"></a>Scirica BM, Morrow DA, Hod H, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. <i>Circulation.</i> 2007;116(15):1647-1652. doi:10.1161/CIRCULATIONAHA.107.724880<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranolazine-drug-information/abstract-text/17804441/pubmed" id="17804441" target="_blank">17804441</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30909832">
<a name="30909832"></a>Scoville BA, Segal JH, Salama NN, et al. Single dose oral ranolazine pharmacokinetics in patients receiving maintenance hemodialysis. <i>Ren Fail</i>. 2019;41(1):118-125. doi:10.1080/0886022X.2019.1585371<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranolazine-drug-information/abstract-text/30909832/pubmed" id="30909832" target="_blank">30909832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15378133">
<a name="15378133"></a>Singh BN, Wadhani N. Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs. <i>J Cardiovasc Pharmacol Ther</i>. 2004;9 Suppl 1:S85-97. doi:10.1177/107424840400900107<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranolazine-drug-information/abstract-text/15378133/pubmed" id="15378133" target="_blank">15378133</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23307553">
<a name="23307553"></a>Southard RA, Blum RM, Bui AH, Blankstein R. Neurologic adverse effects of ranolazine in an elderly patient with renal impairment. <i>Pharmacotherapy</i>. 2013;33(1):e9-e13. doi:10.1002/phar.1152<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranolazine-drug-information/abstract-text/23307553/pubmed" id="23307553" target="_blank">23307553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16875985">
<a name="16875985"></a>Stone PH, Gratsiansky NA, Blokhin A, et al. Antianginal Efficacy of Ranolazine When Added to Treatment With Amlodipine: The ERICA (Efficacy of Ranolazine in Chronic Angina) Trial. <i>J Am Coll Cardiol</i>. 2006;48(3):566-575.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranolazine-drug-information/abstract-text/16875985/pubmed" id="16875985" target="_blank">16875985</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28213480">
<a name="28213480"></a>Strauss DG, Vicente J, Johannesen L, et al. Common genetic variant risk score is associated with drug-induced QT prolongation and torsade de pointes risk: A pilot study. <i>Circulation</i>. 2017;135(14):1300-1310. doi:10.1161/CIRCULATIONAHA.116.023980<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranolazine-drug-information/abstract-text/28213480/pubmed" id="28213480" target="_blank">28213480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24424337">
<a name="24424337"></a>Tarapués M, Cereza G, Arellano AL, Montané E, Figueras A. Serious QT interval prolongation with ranolazine and amiodarone. <i>Int J Cardiol</i>. 2014;172(1):e60-e61. doi:10.1016/j.ijcard.2013.12.061<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranolazine-drug-information/abstract-text/24424337/pubmed" id="24424337" target="_blank">24424337</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32929996">
<a name="32929996"></a>Tisdale JE, Chung MK, Campbell KB, et al; American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing. Drug-induced arrhythmias: A scientific statement from the American Heart Association. <i>Circulation</i>. 2020;142(15):e214-e233. doi:10.1161/CIR.0000000000000905<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranolazine-drug-information/abstract-text/32929996/pubmed" id="32929996" target="_blank">32929996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24803473">
<a name="24803473"></a>Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. <i>Circ Cardiovasc Qual Outcomes</i>. 2013;6(4):479-487. doi:10.1161/CIRCOUTCOMES.113.000152. Erratum in: <i>Circ Cardiovasc Qual Outcomes</i>. 2013;6(6):e57.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranolazine-drug-information/abstract-text/24803473/pubmed" id="24803473" target="_blank">24803473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24803473">
<a name="24803473"></a>Tisdale JE, Jaynes HA, Kingery JR, et al. Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients. <i>Circ Cardiovasc Qual Outcomes</i>. 2014;7(3):381-390. doi:10.1161/CIRCOUTCOMES.113.000651 Erratum in: <i>Circ Cardiovasc Qual Outcomes</i>. 2014;7(6):981.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranolazine-drug-information/abstract-text/24803473/pubmed" id="24803473" target="_blank">24803473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21063462">
<a name="21063462"></a>Vadnais DS, Wenger NK. Emerging clinical role of ranolazine in the management of angina. <i>Ther Clin Risk Manag</i>. 2010;6:517-530. doi:10.2147/TCRM.S4468<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranolazine-drug-information/abstract-text/21063462/pubmed" id="21063462" target="_blank">21063462</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25870186">
<a name="25870186"></a>Vicente J, Johannesen L, Mason JW, et al. Comprehensive T wave morphology assessment in a randomized clinical study of dofetilide, quinidine, ranolazine, and verapamil. <i>J Am Heart Assoc</i>. 2015;4(4):e001615. doi:10.1161/JAHA.114.001615<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranolazine-drug-information/abstract-text/25870186/pubmed" id="25870186" target="_blank">25870186</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19881270">
<a name="19881270"></a>Yao Z, Gong S, Guan T, Li Y, Wu X, Sun H. Synthesis of ranolazine metabolites and their anti-myocardial ischemia activities. <i>Chem Pharm Bull (Tokyo)</i>. 2009;57(11):1218-1222. doi:10.1248/cpb.57.1218<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranolazine-drug-information/abstract-text/19881270/pubmed" id="19881270" target="_blank">19881270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24533675">
<a name="24533675"></a>Yeung E, Krantz MJ, Schuller JL, et al. Ranolazine for the suppression of ventricular arrhythmia: a case series. <i>Ann Noninvasive Electrocardiol.</i> 2014;19(4):345-350. doi:10.1111/anec.12137<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranolazine-drug-information/abstract-text/24533675/pubmed" id="24533675" target="_blank">24533675</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10262 Version 400.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
